357 related articles for article (PubMed ID: 32034077)
21. PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness.
Kaminski L; Torrino S; Dufies M; Djabari Z; Haider R; Roustan FR; Jaune E; Laurent K; Nottet N; Michiels JF; Gesson M; Rocchi S; Mazure NM; Durand M; Tanti JF; Ambrosetti D; Clavel S; Ben-Sahra I; Bost F
Cancer Res; 2019 Jul; 79(13):3268-3280. PubMed ID: 31064849
[TBL] [Abstract][Full Text] [Related]
22. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
[TBL] [Abstract][Full Text] [Related]
23. ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway.
Lee JH; Jang H; Lee SM; Lee JE; Choi J; Kim TW; Cho EJ; Youn HD
FEBS J; 2015 Jan; 282(2):361-71. PubMed ID: 25367309
[TBL] [Abstract][Full Text] [Related]
24. A PGC1α-mediated transcriptional axis suppresses melanoma metastasis.
Luo C; Lim JH; Lee Y; Granter SR; Thomas A; Vazquez F; Widlund HR; Puigserver P
Nature; 2016 Sep; 537(7620):422-426. PubMed ID: 27580028
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation.
Guo Q; Kang H; Wang J; Dong Y; Peng R; Zhao H; Wu W; Guan H; Li F
J Bone Miner Res; 2021 Oct; 36(10):2065-2080. PubMed ID: 34155695
[TBL] [Abstract][Full Text] [Related]
26. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
[TBL] [Abstract][Full Text] [Related]
27. Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis.
Kumari R; Deshmukh RS; Das S
Nat Commun; 2019 Sep; 10(1):4255. PubMed ID: 31534141
[TBL] [Abstract][Full Text] [Related]
28. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
29. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Migita T; Narita T; Nomura K; Miyagi E; Inazuka F; Matsuura M; Ushijima M; Mashima T; Seimiya H; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y
Cancer Res; 2008 Oct; 68(20):8547-54. PubMed ID: 18922930
[TBL] [Abstract][Full Text] [Related]
30. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas.
Beckner ME; Fellows-Mayle W; Zhang Z; Agostino NR; Kant JA; Day BW; Pollack IF
Int J Cancer; 2010 May; 126(10):2282-95. PubMed ID: 19795461
[TBL] [Abstract][Full Text] [Related]
31. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms.
Zaidi N; Royaux I; Swinnen JV; Smans K
Mol Cancer Ther; 2012 Sep; 11(9):1925-35. PubMed ID: 22718913
[TBL] [Abstract][Full Text] [Related]
32. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
33. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
[TBL] [Abstract][Full Text] [Related]
34. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith MP; Ferguson J; Arozarena I; Hayward R; Marais R; Chapman A; Hurlstone A; Wellbrock C
J Natl Cancer Inst; 2013 Jan; 105(1):33-46. PubMed ID: 23250956
[TBL] [Abstract][Full Text] [Related]
35. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML
Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358
[TBL] [Abstract][Full Text] [Related]
36. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
[TBL] [Abstract][Full Text] [Related]
37. Melanoma addiction to the long non-coding RNA SAMMSON.
Leucci E; Vendramin R; Spinazzi M; Laurette P; Fiers M; Wouters J; Radaelli E; Eyckerman S; Leonelli C; Vanderheyden K; Rogiers A; Hermans E; Baatsen P; Aerts S; Amant F; Van Aelst S; van den Oord J; de Strooper B; Davidson I; Lafontaine DL; Gevaert K; Vandesompele J; Mestdagh P; Marine JC
Nature; 2016 Mar; 531(7595):518-22. PubMed ID: 27008969
[TBL] [Abstract][Full Text] [Related]
38. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
39. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer.
Osugi J; Yamaura T; Muto S; Okabe N; Matsumura Y; Hoshino M; Higuchi M; Suzuki H; Gotoh M
Lung Cancer; 2015 Jun; 88(3):310-8. PubMed ID: 25837797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
